Every 424B that Traws Pharma, Inc. (TRAW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TRAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRAW filings page.
Traws Pharma, Inc. is activating an at-the-market equity program under an existing shelf registration, allowing it to sell up to $5,575,709 of common stock through Citizens JMP Securities on a discretionary, from‑time‑to‑time basis. Shares may be sold on Nasdaq under the symbol TRAW or via other permitted methods, with Citizens earning a 3.0% commission on gross proceeds and being deemed an underwriter.
The company’s broader shelf capacity is $139,185,641.25, but this supplement covers only the ATM tranche. As of June 30, 2026, it had 15,228,328 shares outstanding, and illustrative math assumes selling 7,965,299 shares at $0.70, bringing total shares to 23,193,627, though actual sales and prices may differ. Proceeds are expected to support clinical and preclinical programs, other R&D, and general corporate purposes.
The company reports an accumulated deficit of $647.1 million and cash of about $5.0 million, and discloses substantial doubt about its ability to continue as a going concern beyond the first quarter of 2027 without additional funding. It also highlights Nasdaq listing-compliance history, dilution risk from this and future financings, and its status as a smaller reporting company with reduced disclosure requirements.
TRAW amended its prospectus supplement to increase its at-the-market (ATM) capacity. Up to $3,128,399 of additional common stock, by aggregate gross sales price, may be offered and sold from time to time under the ATM Agreement with Citizens JMP Securities, LLC.
The supplement states the company previously sold 3,607,270 shares for aggregate gross proceeds of $7,710,729.46 under the ATM Agreement. It reports a $1.62 closing price on May 20, 2026 and cites an aggregate market value of common stock held by non-affiliates of $32,153,972 based on 14,483,771 shares and a March 23, 2026 price of $2.22.
Traws Pharma, Inc. files a resale prospectus registering up to 35,897,514 shares of Common Stock for resale by selling stockholders. The shares include 4,993,412 Initial Shares and up to 30,904,102 shares issuable upon exercise of Pre-Funded Warrants and Series A, B and C Warrants. The Company is not selling any shares under this prospectus and will receive no proceeds from resale; however, the Company would receive cash proceeds only if Warrants are exercised for cash. The prospectus notes a beneficial ownership limit on exercises (4.99% or, optionally, 9.99%) and describes warrant exercise conditions tied to regulatory milestones, shareholder approval and registration effectiveness. Shares outstanding were 15,150,669 as of April 24, 2026 as used for the selling-stockholder table.